July 30, 2016 5:01 PM ET

Life Sciences Tools and Services

Company Overview of Sarah Cannon Research Institute, LLC

Company Overview

Sarah Cannon Research Institute, LLC, a research organization, conducts clinical research programs in the United States. It conducts community-based clinical trials in oncology, cardiology, gastroenterology, internal medicine, pediatrics, obstetrics and gynecology, dermatology, allergy, and ENT. The company provides research site support services to its pharmaceutical and biotechnology partners, which include project management, data management and safety monitoring, oncology research, clinical monitoring, drug development, site qualification, regulatory, safety, quality assurance, medical writing, scientific analysis, and contracting and budget services, as well as biostatistics and site pa...

3322 West End Avenue

Suite 900

Nashville, TN 37203

United States

Founded in 1993

Phone:

615-329-7274

Key Executives for Sarah Cannon Research Institute, LLC

Chief Executive Officer
Co-Founder and Principal Investigator of Sarah Cannon Research Institute
Chief Financial Officer
Chief Medical Officer and President of Clinical Operations
President of Scri Services
Compensation as of Fiscal Year 2016.

Sarah Cannon Research Institute, LLC Key Developments

Sarah Cannon and StafaCT, Inc. Announce Partnership in Developing New Technology for Comprehensive Electronic Blood and Marrow Transplantation

Sarah Cannon and StafaCT, Inc. announced their partnership in developing new technology for comprehensive electronic blood and marrow transplantation (BMT). Together, the partners created Stafa, a software focused on elevating patient care by managing the transplantation process and supporting the ability to monitor FACT compliance and process improvement. Across the industry, blood and marrow transplantation data has historically been recorded through paper documentation. In an effort to route patients and stem cell products seamlessly through the transplant process, Sarah Cannon Blood Cancer Network sought an electronic system. With the development of this software, Sarah Cannon’s BMT programs now have access to a comprehensive patient management software to track stem cell products from collection through infusion, and provide more effective long-term care management. Sarah Cannon Blood Cancer Network programs that have adopted the use of the software include: Texas Transplant Institute at Methodist Hospital in San Antonio, TX, St. David’s South Austin Medical Center in Austin, TX, and OU Medical Center in Oklahoma City, Okla. The remaining network programs will begin using the software by the end of 2016. Given the successful deployment and pilot results of the technology over the last three years, Sarah Cannon and StafaCT are working together to develop additional functionality and enhancements to the software. Plans include the design and integration of clinical pathways decision support and monitoring, post-transplant care management, as well as several other features to support compliance management.

Sarah Cannon, Hospital Corporation of America and StafaCT, Inc. Announce Partnership in Developing New Technology for Comprehensive Electronic Blood and Marrow Transplantation

Sarah Cannon, Hospital Corporation of America and StafaCT, Inc. announced their partnership in developing new technology for comprehensive electronic blood and marrow transplantation (BMT). Together, the partners created Stafa, a software focused on elevating patient care by managing the transplantation process and supporting the ability to monitor FACT compliance and process improvement.

Eli Lilly and Sarah Cannon Research Institute Partner to Co-Develop New Cancer Therapy

Eli Lilly and Company and Sarah Cannon Research Institute have announced a strategic partnership to co-develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway. The partnership supports the development of this novel targeted cancer therapy, including flexible and efficient program design and implementation, as well as more rapid patient enrollment to clinical trials by accessing SCRI's large network of patients.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sarah Cannon Research Institute, LLC, please visit www.sarahcannon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.